Phase II study of TLK286 [canfosfamide; TELCYTA; Telik] for the treatment of advanced non-small cell lung cancer

Trial Profile

Phase II study of TLK286 [canfosfamide; TELCYTA; Telik] for the treatment of advanced non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2013

At a glance

  • Drugs Canfosfamide (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Actual end date (Aug 2002) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2007 Clinical hold removed by FDA - status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top